Objective: The objectives of this study were to determine the maximum tolerated dose (MTD) and recommended dose (RD) of S-1 plus cisplatin (CDDP) and to evaluate safety and efficacy using the defined RD in advanced/recurrent head and neck cancer (HNC). Methods: S-1 was administered orally at 40 mg/m 2 twice daily for 14 consecutive days, and CDDP was infused on day 8 at a dose of 60 and 70 mg/m 2 . Each course was repeated every 4 weeks. Results: A total of 38 patients were registered, 10 patients for the Phase I study and an additional 28 patients for the Phase II study. Although no dose-limiting toxicity (DLT) was observed in the CDDP 60 mg/m 2 (Level 1) group, two of six patients in the CDDP 70 mg/m 2 (Level 2) group exhibited DLT (fatigue/diarrhea). The MTD was not achieved in the Phase I study. Level 2 was therefore determined as the RD. In the Phase II study, 34 patients, including 6 patients from the Phase I study, were evaluated. At the termination of treatment, the confirmed response rate was 44.1% (15/34, 95% CI: 27.4 -60.8). The best response rate without an adequate duration time was 67.6% (95% CI: 51.9 -83.4). The median survival period was 16.7 months, and the 1-year survival rate was 60.1%. The main toxicities of Grade 3 or above were anorexia (26.5%), nausea (14.7%), neutropenia/thrombocytopenia (11.8%) and anemia/fatigue (8.8%).
INTRODUCTION
As clinical characteristics of head and neck cancer (HNC), $90% of the cases are squamous cell carcinoma, and two-thirds of the patients suffer from locoregional advanced (Stages III and IV) disease. Although the prognosis for earlystage (Stages I and II) HNC is satisfactory with 5-year survival rates of 70 -90% after standard therapy such as surgery, radiotherapy or both (1), the 5-year survival rate falls to ,50% in the locoregional advanced stage, even if radical treatment such as surgery, radiotherapy or chemotherapy [at the induction/concurrent chemoradiotherapy (CCRT)] is performed.
For patients suffering from incurable cancer or recurrent disease, either locoregionally or in the form of distant metastasis, the prognosis is particularly poor, with a median survival period of only 6 months with conventional palliative chemotherapy (1) . Some combination therapies, including cisplatin (CDDP), were devised after Wittes et al. (2) reported the efficacy of CDDP for HNC in 1977, and the efficacy became clear (3, 4) . Since Kish et al. (5) reported the efficacy of CDDP plus 5-fluorouracil (5-FU) combination therapy (CDDP/5-FU) in 1982, moreover, CDDP/5-FU has been considered the most common combination chemotherapy, and it has been widely employed as the first-line chemotherapy for advanced/recurrent HNC. The response rate for CDDP/5-FU has been reported to be 50 -90% (6 -8) when used as the first-line induction chemotherapy and to be 32 -48% (3, 9) when used as second-line or later recurrent chemotherapy. CDDP/5-FU requires long-term hospitalization, however, because it involves continuous infusion of 5-FU and requires adequate support for mucosal and renal toxicity.
S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) is a novel oral anticancer agent consisting of tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) at a molar ratio of 1:0.4:1, based on biochemical modulation of 5-FU (10) . S-1 showed high response rates of 28.8 -46.2% with acceptable toxicity in Phase II studies for advanced/recurrent HNC conducted in Japan (11, 12) . It was approved for HNC in Japan under the approval regulation system in 2001. If the efficacy and toxicities of S-1 plus CDDP combination therapy (S-1/CDDP) were similar to those of CDDP/5-FU in this study, it is thought that it would become one of the potential choices as chemotherapy for advanced/recurrent HNC.
PATIENTS AND METHODS

PATIENT SELECTION
The following eligibility criteria were used: histologically or cytological confirmed HNC (excluding thyroid cancer), unresectable locally advanced (Stage III/IV disease) and recurrent or distant metastasis, at least measurable disease after prior treatment. If the patients had received prior treatment, radiotherapy more than 28 days, surgery and chemotherapy or adjuvant chemotherapy more than 14 days was required before registration. Other eligibility criteria included the following: age 20 -80 years, Eastern Cooperative Oncology Group (ECOG) performance status 0 -1, life expectancy .3 months, adequate bone marrow, hepatic and renal functions (reflected by an absolute hemoglobin level of .9.0 g/dl, leukocyte count . lower limit of normal, platelet count .100 Â 10 29 cells/l, normal bilirubin level of ,1.5 mg/dl, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels ,2.5 times the upper limit of normal, serum creatinine level , upper limit of normal and creatinine clearance .70 ml/min). Within 14 days before registration, all patients underwent a complete physical examination that included their medical history, blood count, serum biochemistry tests (hepatic and renal function tests and electrolytes), urinalysis and echocardiography; a chest radiograph (X-ray) and computed tomography (CT) or magnetic resonance imaging scans of all disease sites were obtained during the 28 days before registration. Patients who had undergone induction chemotherapy with CDDP/5-FU or platinum-based chemotherapy were excluded from the Phase II study unless it used a lower dose as a sensitizer of CCRT. The exclusion criteria were as follows (summary): severe drug hypersensitivity, pulmonary fibrosis or interstitial pneumonia, severe heart disease, difficult-to-control diabetes, active infection or acute inflammation, active concomitant malignancy, and other serious medical conditions. Patients were required to give written informed consent before admission to the study. The study protocol was approved by the instruction review board of each participating hospital, and the study was conducted in accordance with the Japanese Good Clinical Practice guideline. For the first step, three patients were treated at the Level 1 dose. They would then go to Level 2 if no patient showed dose-limiting toxicity (DLT). If one or two of the three patients in the first step showed any DLT, three additional patients were to be enrolled at the same dose level. A dose level would be determined as maximum tolerated dose (MTD) if more than three of six patients showed DLT. The recommended dose (RD) was to be one level below the MTD level.
PHASE II STUDY
A treatment regimen with the RD determined in the Phase I study was repeated every 4 weeks at least two cycles unless progression or unacceptable toxicity occurred. The next course was started for patients whose organ biological parameters had been maintained at the level of the eligibility criteria (leukocyte count .3000 mm 23 , platelet count .75 Â 10 29 cells/l and non-hematologic toxicity .Grade 2).
If these criteria were satisfied 3 weeks after day 1 of each cycle of chemotherapy, the next cycle could be administered. The doses of S-1 were adjusted according to the degree of hematologic and non-hematologic toxicities. The dose was reduced by one level, 20 mg/day, in patients whose BSA was .1.25 m 2 , with evidence of Grade 4 hematologic toxicity or Grade 3 or greater non-hematologic toxicity during any phase of the administration cycle. If a patient with a BSA of ,1.25 m 2 experienced the above toxicities, no further treatment with S-1 was conducted. If treatment was stopped for !4 weeks, the patient was withdrawn from the study.
DEFINITIONS OF DLT AND MTD
Toxicity was evaluated according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), version 2.0. DLT was defined as Grade 4 leukocytopenia or thrombocytopenia, Grade 4 neutropenia lasting for 4 days, occurrence of neutropenic fever (!388C) with Grade 3 leukocytopenia or neutropenia, any Grade 3 non-hematologic toxicity except nausea, vomiting or anorexia following related events occurring in the first course. Patients were also categorized in the DLT group when the second course of treatment was not resumed within 21 days after the first course. The MTD was defined as the dose at which 50% (3/6) or more patients experienced DLT during the first course.
EVALUATION AND FOLLOW-UP
Examinations of blood chemistry and symptoms of toxicity were repeated weekly. The clinical response was measured for each course based on the CT scans or X-ray findings that initially had been used to define the tumor extent. Toxicities were graded according to the NCI-CTC, version 2.0. Tumor responses were evaluated according to the criteria of the World Health Organization (1979), which was an evaluation standard in Japan at the time of the start of this study. Complete response (CR) was defined as the disappearance of all measurable and assessable diseases for at least 4 weeks. Partial response (PR) was defined as a !50% reduction in the sum of the products of the largest diameters of the measurable disease for at least 4 weeks. Stable disease (SD) was defined as failure to observe a PR or CR or progression of the disease for at least 4 weeks. Progressive disease (PD) was defined as a !25% increase in the sum of the products of the largest diameters of the measurable disease or the appearance of new lesions. We conducted assessment meetings for mutual assessment of patient's eligibility and their response to treatment.
STATISTICAL ANALYSIS
The primary objective of the Phase I study was to determine the MTD and RD, and the secondary objective was evaluation of the safety. In the Phase II study, the primary objective was to evaluate efficacy using the defined RD, and the secondary objective was evaluation of the safety and survival.
The number of the Phase II study patients to be enrolled in this study was calculated as !26, which was required to offset the null hypothesis that the lower bound of 95% CI of the expected response rate (65%) would be ,35% under conditions of an a error of 0.05 and a b error of 0.2. The overall survival of eligible patients was defined from the start of treatment to death or the last follow-up visit and was estimated by the Kaplan -Meier method.
RESULTS
Between July 2002 and June 2004, 10 patients were entered in the Phase I study and 28 were entered in the Phase II study to confirm the efficacy and toxicities at the RD.
All patients were eligible for the toxicity evaluation for the total course and for objective response evaluations (Table 1 ). In the Phase I study, because one patient might have contravened the exclusion criteria, active infection or acute inflammation after registration, four patients were enrolled in the Level 1 group. In the Phase II study at the RD including six patients of the Phase I study, 18 patients with unresectable advanced HNC were enrolled, which included 1 patient with distant metastasis (lung and liver). Twenty patients with recurrent HNC included five patients with distant metastasis (lung, skin and bone) who had received prior therapy (surgery, radiation, chemotherapy or more than one) and 10 patients had previously received CCRT with the docetaxel or platinum anticancer agents (carboplatin and CDDP) and other anticancer agents (5-FU, tegaful/uracil and methotrexate). A total of 75 courses were administered: a total of 6 courses at Level 1 in the Phase I study (median: 2 courses, range: 1 -2) and a total of 69 courses at the RD (median: 2 courses, range: 1 -3).
DETERMINATION OF MTD AND DLT
The toxicities (drug-related adverse events) observed during the first course are shown in Table 2 . DLT was not observed at Level 1. At dose level 2, two of six patients showed DLT, one of them Grade 3 diarrhea and the other Grade 3 fatigue. The MTD was not achieved in the Phase I study. Dose level 2 was therefore determined to be RD in the subsequent Phase II study according to the provisions stated in the protocol.
SAFETY
The toxicities observed among 34 patients, including 6 patients in Level 2 in the Phase I study, are shown in Table 2 . The most common toxicities and incidences were hematologic toxicities (64.7 -94.1%), gastrointestinal (GI) dysfunction (79.4 -82.4%) and fatigue (58.8%). The toxicities of Grade 3 or above observed were anorexia (26.5%), nausea (14.7%) and fatigue (8.8%). The hematologic toxicities of Grade 3 or above observed were 11.8% in this study, and granulocyte colony-stimulating factor was administered to one patient. The number of confirmed treatment-related
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Phase I/II study of S-1 plus cisplatin combination chemotherapy deaths in this study was one, a patient who died of pneumonia accompanied by sepsis for Grade 3 leukocytopenia.
RESPONSE AND SURVIVAL
A total of 34 patients were evaluated to determine the response rate at the RD (Tables 3 and 4) . The confirmed response rate (C-RR) with .4-week duration was 44.1% (15/34, 95% CI: 27.4 -60.8). There were 2 CRs (5.9%), 13 PRs included 3 distant metastasis which was 2 lungs and skin (PR: 38.2%), 15 cases of SD (44.1%) and 3 cases of PD (8.8%). In the subgroup analysis, the C-RRs per classification were advanced HNC 44.4% (8/18, 95% CI: 24.6 -66.3) and recurrent HNC 43.8% (7/16, 95% CI: 19.4 -68.1).
The median time to progression in the Phase II study (28 patients) was 100 days (range: 70 -140). The median time to PR (50% tumor reduction) and the median overall duration of response in 11 responding patients were 25 days (range: 17 -56) and 61 days (range: 38 -116), respectively.
We additionally considered the best responses, including patients with a duration time of ,4 weeks. The best overall response was 67.6% (95% CI: 51.9 -83.4). Among the best responses, there were seven cases of CR (20.6%), 16 of PR (47.1%), seven of SD (20.6%) and three of PD (8.8%). In the subgroup analysis, the best overall responses per classification were advanced HNC 72.2% (13/18, 95% CI: 51.5 -92.9) and recurrent HNC 62.5% (10/16, 95% CI: 38.8-86.2).
The median survival time (MST) of 34 patients was 16.7 months (95% CI: 11.4 -no data), whereas the 1-year survival rates were 60.1% (Fig. 1) . In the subgroup analysis, the 1-year survival rate for advanced HNC was 83.0%, and MST for recurrent HNC was 9.8 months (95% CI: 7.5 -13.3) and the 1-year survival rate was 34.4% (Fig. 2) . The median follow-up time for survival analysis was 13.1 months (range: 1.84 -28.4). The detail of the treatment for 18 patients with advanced HNC after this regimen end was as follows: 8 patients received CCRT, 6 received radiotherapy, 2 received surgery and 2 were untreated. In addition, for 16 patients with recurrent cancer, 2 patients received CCRT, 2 received radiotherapy, 1 received surgery, 5 received adjuvant chemotherapy and 6 were untreated. toxicity, based on biochemical modulation of 5-FU (10). S-1 was consequently approved in Japan for gastric cancer under an accelerated approval regulation system in 1999 (13, 14) and subsequently for HNC in 2001 (11, 12) , colorectal cancer in 2003 (15, 16) , non-small lung cancer (NSCLC) in 2004 (17, 18) , breast cancer in 2006 (19) , and pancreatic cancer (20, 21) and biliary tract cancer in 2007 (22) , and clinical trials of its use for renal cell cancer, prostate cancer, liver cancer and cervical cancer are currently under way. In other carcinomas, S-1/CDDP was carried out for advanced gastric cancer (AGC) and NSCLC with response rates of 76% (23) and 47% (24) , and acceptable toxicities. In addition, a randomized Phase III study for AGC patients as the first-line chemotherapy, the SPIRITS study, was reported and proved the superiority of S-1/CDDP to S-1 monotherapy (25) . The response rate for combination therapy versus monotherapy was 54.0% versus 31% (P ¼ 0.0018), and the MST was 13.0 versus 11.0 months (median follow-up time 34.6 months; hazard ratio 0.774; P ¼ 0.0366). This study and other studies on combination therapy for HNC with S-1 plus CDDP analogues, S-1 plus carboplatin combination therapy (S-1/carboplatin) (26) and S-1 plus nedaplatin combination therapy (S-1/nedaplatin) (27) have been conducted since 2002, and the results of these studies have been reported. S-1/CDDP (75 mg/m 2 ) was also performed in Korea as the first-line remission induction therapy for advanced clinical Stage III/ IV cancer, and a high response rate of 89.7% was reported (28) .
In this study of S-1/CDDP administration for advanced/ recurrent HNC performed this time, the toxicities observed were mild and acceptable in light of the safety of this combination therapy. As concerns efficacy in this study, the C-RR was 44.1% (95% CI: 27.4 -60.8), which was lower than the expected response rate of 65% to ,35% under these (27) for studies performed in Japan.
The response rate for S-1/CDDP for advanced cancer was lower than the response rates (50 -90%) for 5-FU/CDDP (6 -8) . Suggested reasons for the lower response rate for advanced cancer included the short duration of the average of two administration courses (28) and the involvement of the treatment system for locoregional advanced cancer. The treatment system for locoregional advanced cancer was specified as follows. If chemotherapy is performed as prior treatment, perform two target courses of the therapy and make a decision on the form of treatment to follow according to the therapeutic efficacy at the end of the second course. If the effectiveness evaluation is SD at the end of one course of the preceding chemotherapy, perform radiotherapy or surgery with the addition of postoperative radiotherapy. If PR (50% tumor reduction) is achieved at the end of one course of the preceding chemotherapy, add a second course. If PR continues at the end of second course, perform radiotherapy or surgery with the addition of post-operative radiotherapy; and if CR is achieved, add another course of chemotherapy with radiation irradiation to complete the treatment. As an exception in this study, when a tumor achieved reduction of .50%, we considered the benefit to the patient and allowed the next treatment to be conducted based on the judgment of the doctor. In this study, three of the eight patients with advanced HNC who were evaluated as SD in C-RR showed tumor reduction of .50%, as in the case of five patients administered a second therapy (radiotherapy, chemoradiotherapy) without waiting for the 28-day duration of effect with patient benefit taken into consideration. Considering the action of these results, the best response rate for advanced cancer was 77.2% (95% CI: 51.5 -92.9) in this study.
The MST in this study was 16.7 months, and the 1-year survival rate was 60.1%. MST in recurrent cancer was 9.8 months with a 1-year survival rate of 34.4%. These results were comparable to those for cetuximab/CDDP (33), gefitinib/methotrexate (34) , docetaxel/CDDP (29) , paclitaxel/ CDDP (30) and S-1/carboplatin (26) . In advanced cancer, the 1-year survival rate was 83.0%, although the observation period was short, and this result was closely similar to that for 5-FU/CDDP (6 -8) .
As concerns safety, the most common toxicities in this study were hematologic toxicity and GI dysfunction and fatigue, and the hematologic toxicity was mild when compared with the results for conventional 5-FU/CDDP (3,6 -9), with an incidence of 11.8%. The results of this study indicated that S-1/CDDP can be considered to be effective with acceptable toxicities for advanced/recurrent HNC. With respect to recurrent HNC, it was determined that a Phase III comparative study with a CDDP base was necessary, among other things. As concerns locoregional advanced HNC, it is desirable to carry out CCRT. S-1 exhibits radiosensitization action and it is often used in combination with radiation therapy. Tahara et al. (31, 32) conducted a Phase I study of CCRT with S-1/CDDP for unresectable advanced HNC and suggested its utility. We plan to conduct a Phase II multicentred trial as a JCOG study.
